SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : RNAi
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thomas who wrote (299)11/25/2004 4:29:44 PM
From: Walkingshadow  Read Replies (1) of 671
 
Hi Thomas,

I happen to work in this field.

I can tell you that paper in Nature from the European arm of ALNY was a huge advance.

It opens the door to many clinical possibilities, and people are all over this.

But it is helpful to read the recent commentary in Science... RNA interference is not without problems. Off-target effects seem to be much more common than initially realized, but technical advances to detect and minimize this have developed pretty rapidly also.

The guys running ALNY are the best in the world, head and shoulders above the other RNA interference-related companies. Of course, anybody who followed CRA and Craig Venter knows how these things typically work out in the long run---the MBAs always eventually get rid of the PhDs. But still, you can count on ALNY to be a leader in the field.

The one I am waiting for is Benitec, a company on the Australian exchange which is supposed to IPO here early next year.

(Disclosure: I don't own ALNY)

WS
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News